GO:0042760 very long-chain fatty acid catabolic process: Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0042760 describes the breakdown of very long-chain fatty acids (VLCFAs), defined as fatty acids with aliphatic tails longer than 22 carbons.
• VLCFA catabolism occurs primarily in peroxisomes and involves initial chain shortening by beta-oxidation, followed by mitochondrial oxidation of shorter products.
• Key enzymes include acyl-CoA oxidases, multifunctional proteins, and thiolases, with transport proteins such as ABCD1 facilitating VLCFA entry into peroxisomes.
• Defects in VLCFA catabolism cause X-linked adrenoleukodystrophy and other peroxisomal disorders, making this pathway a therapeutic target.
• Research tools include CRISPR knockout models, flux analysis, and lipidomics to dissect gene function in VLCFA catabolism.
• Understanding VLCFA catabolism is relevant to metabolic diseases, cancer, and neurodegeneration, with emerging links to dietary lipid sensing.
Description
Very long-chain fatty acid catabolic process (GO:0042760) is a biological process that encompasses the chemical reactions and pathways resulting in the breakdown of very long-chain fatty acids (VLCFAs), which are fatty acids with aliphatic tails containing more than 22 carbons. This process is essential for cellular energy homeostasis and lipid metabolism, as VLCFAs cannot be efficiently oxidized by mitochondria and require peroxisomal beta-oxidation for initial chain shortening. Dysregulation of VLCFA catabolism leads to accumulation of VLCFAs, which is associated with severe metabolic and neurological disorders, including X-linked adrenoleukodystrophy. Researchers study this pathway to understand peroxisomal biology, lipid trafficking, and the metabolic basis of disease, as well as to identify therapeutic targets. The process is highly conserved from plants to humans, with plant VLCFA catabolism playing roles in wax biosynthesis and stress responses.
very long-chain fatty acid catabolic process At A Glance
| GO ID | GO:0042760 |
|---|---|
| GO term | very long-chain fatty acid catabolic process |
| Ontology | biological_process |
| Synonym | very-long-chain fatty acid breakdown; very-long-chain fatty acid catabolic process; very-long-chain fatty acid catabolism; very-long-chain fatty acid degradation |
| Major function | Breakdown of fatty acids with aliphatic tails longer than 22 carbons |
| Subcellular location | Peroxisome (initial steps), mitochondria (subsequent oxidation) |
| Key enzymes | Acyl-CoA oxidase, multifunctional protein, thiolase |
| Related pathways | Peroxisomal beta-oxidation, mitochondrial beta-oxidation, lipid metabolism |
What Is GO:0042760?
GO:0042760, very long-chain fatty acid catabolic process, is defined by the Gene Ontology as the chemical reactions and pathways resulting in the breakdown of a very long-chain fatty acid, where a very long-chain fatty acid has an aliphatic tail containing more than 22 carbons. This process includes the activation of VLCFAs to acyl-CoA esters, their transport into peroxisomes, and their stepwise beta-oxidation to shorten the chain, ultimately yielding acetyl-CoA and shorter fatty acids that can be further oxidized in mitochondria.
Why Is very long-chain fatty acid catabolic process Important in Cell Biology?
Very long-chain fatty acid catabolic process is critical for maintaining lipid homeostasis and energy balance, as impaired breakdown leads to the accumulation of VLCFAs, which are toxic and disrupt membrane integrity and cellular function. This process is particularly important in tissues with high metabolic demand, such as the brain and heart, where peroxisomal and mitochondrial fatty acid oxidation are essential. Defects in VLCFA catabolism are linked to peroxisomal disorders, including X-linked adrenoleukodystrophy, and contribute to the pathophysiology of metabolic syndrome and neurodegeneration. Understanding this pathway provides insights into lipid metabolism and offers potential targets for therapeutic intervention.
• Maintains cellular lipid homeostasis by preventing toxic accumulation of VLCFAs.
• Provides energy through beta-oxidation of VLCFAs, especially in peroxisomes and mitochondria.
• Dysfunction causes X-linked adrenoleukodystrophy and other peroxisomal disorders.
• Plays a role in brain development and function due to high lipid content.
• Involved in plant wax biosynthesis and stress responses, highlighting evolutionary conservation.
• Linked to metabolic diseases such as obesity and insulin resistance through lipid sensing.
• Serves as a model for studying peroxisomal protein import and beta-oxidation.
• Potential target for cancer therapy, as cancer cells reprogram lipid metabolism.
• Relevant to dietary lipid processing and infant nutrition.
• Enables research on fatty acid chain length specificity and enzyme evolution.
What Happens During very long-chain fatty acid catabolic process?
Activation and Transport of VLCFAs
In simple terms: First, very long-chain fatty acids are converted into a form that can enter the peroxisome.
VLCFAs are activated to very long-chain acyl-CoA esters by acyl-CoA synthetases, a step required for their metabolism. These acyl-CoA esters are then transported into peroxisomes, primarily via ABCD1 (ALDP), a peroxisomal membrane transporter. Defects in ABCD1 lead to accumulation of VLCFAs, as seen in X-linked adrenoleukodystrophy.
Peroxisomal Beta-Oxidation
In simple terms: Inside peroxisomes, the fatty acid chain is shortened step by step.
Peroxisomal beta-oxidation begins with acyl-CoA oxidase, which introduces a double bond and generates hydrogen peroxide. The multifunctional protein (L-bifunctional enzyme) then catalyzes hydration and dehydrogenation, and thiolase cleaves the chain, releasing acetyl-CoA and a shortened acyl-CoA. This cycle repeats until the fatty acid is short enough to be exported to mitochondria for complete oxidation.
Mitochondrial Oxidation of Shortened Products
In simple terms: The shortened fatty acids are then burned for energy in mitochondria.
After peroxisomal chain shortening, medium- and short-chain fatty acids are transported to mitochondria, where they undergo beta-oxidation to generate acetyl-CoA, which enters the TCA cycle. This compartmentalization ensures efficient energy production and prevents mitochondrial overload by VLCFAs.
Regulation of VLCFA Catabolism
In simple terms: The process is turned on or off based on the cell's energy needs and lipid levels.
VLCFA catabolism is regulated by peroxisome proliferator-activated receptors (PPARs), which sense fatty acids and induce expression of genes involved in beta-oxidation. Additionally, malonyl-CoA inhibits mitochondrial fatty acid oxidation, while peroxisomal oxidation is less sensitive, allowing VLCFA breakdown to continue when needed. Hormonal signals such as insulin and glucagon also modulate the pathway.
Key Genes Involved in GO:0042760 very long-chain fatty acid catabolic process
The following genes and proteins are key players in very long-chain fatty acid catabolic process, based on their established roles in peroxisomal and mitochondrial fatty acid oxidation.
| Gene | Major Role | Research Relevance |
|---|---|---|
| ABCD1 | Peroxisomal membrane transporter for VLCFA-CoA | Mutations cause X-linked adrenoleukodystrophy; target for gene therapy |
| ACOX1 | Peroxisomal acyl-CoA oxidase, rate-limiting enzyme | Defects cause peroxisomal acyl-CoA oxidase deficiency; model for beta-oxidation |
| HSD17B4 | Multifunctional protein with hydratase and dehydrogenase activities | Mutations linked to D-bifunctional protein deficiency |
| ACAA1 | Peroxisomal thiolase, cleaves 3-ketoacyl-CoA | Involved in chain shortening; knockout models show VLCFA accumulation |
| CPT1A | Mitochondrial carnitine palmitoyltransferase 1, regulates entry of long-chain fatty acids | Key for mitochondrial oxidation of shortened products |
| CPT2 | Mitochondrial carnitine palmitoyltransferase 2 | Defects cause CPT II deficiency; relevant to fatty acid oxidation disorders |
| ACADVL | Very long-chain acyl-CoA dehydrogenase | Mitochondrial oxidation of long-chain fatty acids; mutations cause VLCAD deficiency |
| PPARA | Nuclear receptor regulating lipid metabolism | Controls expression of beta-oxidation genes; target for fibrates |
| PPARD | Nuclear receptor involved in fatty acid oxidation | Modulates peroxisomal and mitochondrial oxidation |
| SLC25A17 | Peroxisomal solute carrier | Transports metabolites across peroxisomal membrane; affects VLCFA catabolism |
| PEX5 | Peroxisomal targeting signal receptor | Essential for import of beta-oxidation enzymes; defects cause peroxisome biogenesis disorders |
| PEX7 | Peroxisomal targeting signal 2 receptor | Imports thiolase and other enzymes; linked to rhizomelic chondrodysplasia punctata |
| FATP1 | Fatty acid transport protein | Facilitates VLCFA uptake; potential target for metabolic disorders |
| FABP1 | Liver fatty acid binding protein | Binds VLCFAs and directs them to oxidation or storage |
| CER6 | Plant very-long-chain fatty acid elongase | Involved in wax biosynthesis; model for VLCFA elongation and catabolism |
| GL2 | Plant enzyme interacting with CER6 | Part of elongase complex; relevant to plant lipid metabolism |
| ELOVL2 | Elongase of very long-chain fatty acids | Synthesizes VLCFAs; balance with catabolism affects lipid homeostasis |
How Is very long-chain fatty acid catabolic process Regulated?
Very long-chain fatty acid catabolic process is regulated at multiple levels. Peroxisome proliferator-activated receptors (PPARs), particularly PPAR-alpha, sense fatty acid levels and induce expression of genes encoding peroxisomal and mitochondrial beta-oxidation enzymes. Insulin and glucagon reciprocally regulate fatty acid oxidation: insulin promotes storage, while glucagon stimulates oxidation during fasting. Malonyl-CoA, a key metabolite, inhibits mitochondrial CPT1, but peroxisomal VLCFA oxidation is less sensitive, ensuring VLCFA breakdown continues when needed. Additionally, the availability of cofactors such as CoA and NAD+ influences flux through the pathway.
very long-chain fatty acid catabolic process and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| ABCD1 | X-linked adrenoleukodystrophy | ABCD1 knockout mice; patient-derived fibroblasts |
| ACOX1 | Peroxisomal acyl-CoA oxidase deficiency | ACOX1 knockout mice; CRISPR knockout cell lines |
| HSD17B4 | D-bifunctional protein deficiency | Hsd17b4 knockout mice; patient cells |
| PEX5 | Zellweger syndrome spectrum | PEX5 knockout cells; zebrafish models |
| PPARA | Metabolic syndrome, dyslipidemia | PPARA knockout mice; overexpression models |
X-linked Adrenoleukodystrophy (X-ALD)
X-ALD is caused by mutations in ABCD1, leading to impaired VLCFA transport into peroxisomes and accumulation of VLCFAs in tissues, particularly the brain and adrenal glands. This results in demyelination and adrenal insufficiency. Research focuses on restoring VLCFA catabolism through gene therapy or pharmacological induction of alternative peroxisomal transporters.
Peroxisomal Biogenesis Disorders
Mutations in PEX genes, such as PEX5 and PEX7, disrupt peroxisome formation and import of beta-oxidation enzymes, causing severe diseases like Zellweger syndrome. These disorders highlight the essential role of VLCFA catabolism in development and homeostasis.
Metabolic Syndrome and Diabetes
Altered VLCFA catabolism contributes to insulin resistance and dyslipidemia. PPAR-alpha agonists, which enhance fatty acid oxidation, are used to treat hyperlipidemia, underscoring the therapeutic relevance of this pathway.
Cancer
Cancer cells often reprogram lipid metabolism, including fatty acid oxidation, to support growth and survival. Targeting VLCFA catabolism may offer novel therapeutic strategies, as some tumors depend on peroxisomal beta-oxidation.
From very long-chain fatty acid catabolic process-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does gene X regulate VLCFA catabolism? | CRISPR knockout cell line (e.g., HepG2, fibroblasts) |
| What is the effect of a specific point mutation in ABCD1? | Point-mutation knock-in via CRISPR in cell lines |
| Can overexpression of ACOX1 rescue VLCFA accumulation? | Overexpression cell model (lentiviral or CRISPR activation) |
| How does tagging of HSD17B4 affect its localization? | Tagged knock-in (e.g., GFP) using CRISPR |
| What is the flux through VLCFA catabolism? | Stable isotope tracing with 13C-labeled VLCFA in wild-type and KO cells |
| Does PPAR-alpha agonist induce VLCFA catabolism? | Reporter cell line with PPRE-luciferase; wild-type and PPARA KO |
How to Study the very long-chain fatty acid catabolic process Process
| Method | What It Measures | Typical Application |
|---|---|---|
| LC-MS/MS lipidomics | VLCFA and intermediate levels | Quantify VLCFA accumulation in KO cells |
| 13C stable isotope tracing | Flux through beta-oxidation | Assess catabolic rate in wild-type vs mutant |
| CRISPR knockout screen | Genes required for VLCFA catabolism | Identify novel regulators |
| Fluorescence microscopy | Subcellular localization of enzymes | Study peroxisomal import and dynamics |
| Western blot | Protein expression levels | Validate knockout or overexpression |
| qRT-PCR | mRNA expression of beta-oxidation genes | Assess PPAR-alpha target induction |
| Enzyme activity assay | Acyl-CoA oxidase or thiolase activity | Measure catalytic function in vitro |
| Seahorse respirometry | Mitochondrial oxidation of shortened fatty acids | Evaluate mitochondrial function |
Lipidomics and Mass Spectrometry
Lipidomic profiling using LC-MS/MS allows quantification of VLCFA species and their catabolic intermediates, providing direct evidence of pathway activity. This method is essential for validating gene function in VLCFA catabolism.
Flux Analysis with Stable Isotopes
Stable isotope tracing with 13C-labeled VLCFAs followed by mass spectrometry measures the flux through beta-oxidation, revealing how genetic perturbations affect catabolic rates.
CRISPR Screening
Genome-wide CRISPR knockout screens can identify novel genes required for VLCFA catabolism, using cell viability or lipid accumulation as readouts.
Imaging and Subcellular Localization
Fluorescence microscopy with tagged enzymes (e.g., GFP-ACOX1) and organelle markers visualizes peroxisomal dynamics and VLCFA trafficking in live cells.
How CRISPR Can Be Used to Study GO:0042760 very long-chain fatty acid catabolic process
Knockout
CRISPR knockout of genes such as ABCD1 or ACOX1 in cell lines (e.g., HepG2, HeLa) creates models to study VLCFA catabolism defects, leading to VLCFA accumulation and altered lipid profiles. These models are valuable for drug screening and mechanistic studies.
Point Mutation
Introducing disease-associated point mutations (e.g., in ABCD1) via CRISPR base editing or homology-directed repair allows precise modeling of X-ALD and functional analysis of mutant proteins.
Knock-in
Knock-in of tagged versions of beta-oxidation enzymes (e.g., GFP-HSD17B4) enables real-time tracking of protein localization and interactions in peroxisomes.
Overexpression
CRISPR activation (CRISPRa) or lentiviral overexpression of rate-limiting enzymes like ACOX1 can enhance VLCFA catabolism, providing gain-of-function models to study pathway capacity and rescue phenotypes.
How EDITGENE Supports very long-chain fatty acid catabolic process Research
Researchers studying very long-chain fatty acid catabolic process-related genes often need to determine whether a candidate gene is causally involved in VLCFA breakdown, and CRISPR-based models provide a robust approach to establish causality and dissect molecular mechanisms.
Contact EDITGENE today to design your custom CRISPR model for very long-chain fatty acid catabolic process research.
Frequently Asked Questions About very long-chain fatty acid catabolic process
What is very long-chain fatty acid catabolic process?
It is the biological process (GO:0042760) of breaking down fatty acids with more than 22 carbons, primarily in peroxisomes and mitochondria.
What genes are involved in very long-chain fatty acid catabolic process?
Key genes include ABCD1, ACOX1, HSD17B4, ACAA1, CPT1A, and PPARA, among others.
Where does very long-chain fatty acid catabolism occur?
Initial steps occur in peroxisomes, followed by mitochondrial oxidation of shortened products.
What diseases are linked to defects in VLCFA catabolism?
X-linked adrenoleukodystrophy, Zellweger syndrome, and other peroxisomal disorders.
How can I study very long-chain fatty acid catabolic process?
Use CRISPR knockout models, lipidomics, stable isotope tracing, and enzyme activity assays.
What is the role of ABCD1 in VLCFA catabolism?
ABCD1 transports VLCFA-CoAs into peroxisomes for beta-oxidation; mutations cause X-ALD.
Can CRISPR be used to model VLCFA catabolism disorders?
Yes, CRISPR knockout and point mutation models are widely used to study gene function and disease mechanisms.
What are the substrates of peroxisomal beta-oxidation?
Very long-chain acyl-CoAs, which are shortened by acyl-CoA oxidase, multifunctional protein, and thiolase.
How is VLCFA catabolism regulated?
By PPARs, insulin/glucagon, and substrate availability, with malonyl-CoA inhibiting mitochondrial oxidation.
Why is VLCFA catabolism important for brain health?
The brain is rich in lipids; impaired VLCFA breakdown leads to demyelination and neurodegeneration.
Conclusion
Very long-chain fatty acid catabolic process (GO:0042760) is a fundamental metabolic pathway required for lipid homeostasis and energy production. Its dysfunction underlies severe peroxisomal disorders, and ongoing research continues to uncover its regulation and therapeutic potential. CRISPR-based models are invaluable for dissecting gene function and developing targeted therapies for related diseases.
References
- 1. Lopaschuk GD et al.. 2010. Myocardial fatty acid metabolism in health and disease.. Physiol Rev 90(1):207-58 PMID: 20086077
- 2. Nakamura MT et al.. 2014. Regulation of energy metabolism by long-chain fatty acids.. Prog Lipid Res 53:124-44 PMID: 24362249
- 3. Schönfeld P et al.. 2016. Short- and medium-chain fatty acids in energy metabolism: the cellular perspective.. J Lipid Res 57(6):943-54 PMID: 27080715
- 5. Liu Y et al.. 2025. Molecular basis of very-long-chain fatty acid elongation by the CER6-GL2 enzyme complex in plant wax biosynthesis.. Sci Adv 11(49):eadz0135 PMID: 41337596
- 6. He Q et al.. 2023. Cellular Uptake, Metabolism and Sensing of Long-Chain Fatty Acids.. Front Biosci (Landmark Ed) 28(1):10 PMID: 36722264
- 7. Brenna JT et al.. 2022. New understandings of the pathway of long-chain polyunsaturated fatty acid biosynthesis.. Curr Opin Clin Nutr Metab Care 25(2):60-66 PMID: 34937850
- 8. Demmelmair H et al.. 2018. Lipids in human milk.. Best Pract Res Clin Endocrinol Metab 32(1):57-68 PMID: 29549961
